Actinium Pharmaceuticals Inc (ATNM)

Trade ATNM now with
2/22/2018 7:33:07 AM Actinium Announces Commencement Of Rights Offering Subscription Period
2/20/2018 7:32:58 AM Actinium Announces Product Showcase And Other Visibility Extending Activities At The BMT Tandem Meetings
2/8/2018 8:04:38 AM Actinium Names Anil Kapur Chief Commercial Officer
2/6/2018 7:32:53 AM Actinium Pharma Unveils Trial To Study Actimab-A With CLAG-M For Relapsed Or Refractory AML Patients
2/1/2018 7:35:53 AM Actinium Pharma Announces Acceptance Of Abstract Showcases The Potential Of Actinium’s AWE Technology Platform At AACR
1/8/2018 7:33:40 AM Actinium Pharmaceuticals Names Dale Ludwig Chief Scientific Officer
12/27/2017 9:01:14 AM Actinium Update On Phase 3 Trial Of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial Continue
12/12/2017 7:35:14 AM Actinium Highlights Promising Data From AWE Program At ASH
12/11/2017 6:32:43 AM Actinium Reports Positive Preliminary Results From Phase 2 Trial For Actimab
12/6/2017 11:43:19 AM B. Riley FBR Starts Actinium Pharmaceuticals Inc (ATNM) At Buy With $2.75 Price Target
12/5/2017 7:31:38 AM Actinium Pharma Unveils Actimab-MDS And Planned Phase 2 Trial In Myelodysplastic Syndromes
11/14/2017 8:01:45 AM Actinium Launches AWE Program Aka Actinium Warhead Enabling Program To Enable Collaborations Based On Actinium-225 Tech
10/25/2017 7:34:35 AM Actinium Pharma Unveils Activation Of Fifteenth Clinical Trial Site In Phase 3 SIERRA Trial For Iomab-B
10/4/2017 7:31:06 AM Actinium Pharma Provides Update On Actimab-A Phase 2 Clinical Trial For Patients With Acute Myeloid Leukemia
9/14/2017 8:05:35 AM Adgero Biopharma Appoints Felix Garzon As Chief Medical Officer
9/13/2017 7:33:01 AM Actinium Pharma's Actimab-A And Actimab-M Programs To Be Presented At SOHO
8/2/2017 4:23:41 PM Actinium Closes Public Offering Of Common Stock And Warrants To Purchase Common Stock
7/28/2017 9:15:48 AM Actinium Prices Public Offering Of 21.50 Mln Shares And Warrants To Purchase An Aggregate Of 18.28 Mln Shares